Sertaconazole: Updated review of a topical antifungal agent

Expert Review of Anti-Infective Therapy

Volumn 3, Issue 3, 2005, Pages 333-342

  Carrillo Muñoz, Alfonso ^a   Guisiano, Gustavo ^b   Ezkurra, Pliar Ariadna ^c   Quindós, Guillermo ^c  

^a Associacio Catalana d'Intelligencia Artificial   (Spain)

^b UNIVERSIDAD NACIONAL DEL NORDESTE   (Argentina)

^c UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Dermatophytes; Fungi; Mycoses; Sertaconazole; Topical antifungal agent; Yeast

Indexed keywords

BIFONAZOLE; CLOTRIMAZOLE; ECONAZOLE; KETOCONAZOLE; MICONAZOLE; PLACEBO; SERTACONAZOLE;

ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; DERMATOMYCOSIS; DRUG APPROVAL; DRUG EFFICACY; DRUG FORMULATION; DRUG MARKETING; DRUG SAFETY; DRUG STRUCTURE; EUROPE; FOOD AND DRUG ADMINISTRATION; GENOTOXICITY; GRAM POSITIVE COCCI; HUMAN; IN VITRO STUDY; LETHAL DOSE; MAXIMUM TOLERATED DOSE; MYCOSIS; NONHUMAN; ONYCHOMYCOSIS; REVIEW; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TERATOGENICITY; TINEA VERSICOLOR; VAGINA CANDIDIASIS; YEAST;

ANIMALS; ANTIFUNGAL AGENTS; HUMANS; IMIDAZOLES; MYCOSES; THIOPHENES;

EID: 21044437730     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.3.3.333     Document Type: Review

References (52)

1. Carrillo-Muñoz AJ, Quindós G, Lopez-Ribot JL. Current developments in antifungal agents: present and future. Curr. Med. Chem. Anti Infect. Agents. 3(4), 297-323 (2004).
2. Torres J, Márquez M, Camps F. Sertaconazole in the treatment of mycoses: from dermatology to gynecology. Int. J. Gynaecol. Obstet. 71 (Suppl. 1), S3-S20 (2000).
3. Raga MM, Moreno-Manas M, Cuberes MR, Palacín C, Castello JM, Ortíz JA. Synthesis and antimycotic activity of (benzo[b]thienyl)methyl ethers of 1-(2,4-dichlorophenyl)-2- (1H-imidazol-1-yl)-ethanol and of (Z)-1-(2,4-dichlorophenyl)-2- (1H-imidazol-1-yl)ethanone oxime. Arzneimittelforschung 42(5A), 691-694 (1992).
4. Albet C, Fernández JM, Sacristán A, Ortíz JA. Physicochemical properties, analytical determinations and stability of sertaconazole nitrate. Arzneimittelforschung 42(5A), 695-698 (1992).
5. Agut J, Palacín C, Sacristán A, Ortíz JA. Inhibition of ergosterol synthesis by sertaconazole in Candida albicans. Arzneimittelforschung 42(5A), 718-720 (1992).
6. Drouhet E, DuPont B. In vitro antifungal activity of sertaconazole. Arzneimittelforschung 42(5A), 705-710 (1992).
7. Agut J, Palacín C, Salgado J, Casas E, Sacristán A, Ortíz JA. Direct membrane-damaging effect of sertaconazole on Candida albicans as a mechanism of its fungicidal activity. Arzneimittelforschung 42(5A), 721-724 (1992).
8. Palacín C, Sacristán A, Ortiz JA. In vitro activity of sertaconazole. Arzneimittelforschung 42(5A), 699-705 (1992).
9. Figueras MJ, Cano JF, Guarro J. Ultrastructural alterations produced by sertaconazole on several opportunistic pathogenic fungi. J. Med. Vet Mycol. 33(6), 395-401 (1995).
10. Carrillo-Munoz AJ, Tur-Tur C, Hernández-Molina JM. Comparación de dos métodos para el estudio de la sensibilidad in vitro de sertaconazol a levaduras de origen clínico. Rev. Esp. Quimioter. 12(1), 58-63 (1999).
11. Carrillo-Munoz AJ, Tur-Tur C, Bornay-Llinares FJ, Arévalo P. Comparative study of the in vitro antifungal activity of bifonazole, naftifine and sertaconazole against yeasts. J. Chemother. 11(3), 187-190 (1999).
12. Carrillo-Munoz AJ, Tur-Tur C. Comparative study of antifungal activity of sertaconazole, terbinafine, and bifonazole against clinical isolates of Candida spp., Cryptococcus neoformans and dermatophytes. Chemotherapy 43(6), 387-392 (1997).
13. Carrillo-Munoz AJ, Tur C, Torres J. In vitro antifungal activity of sertaconazole, bifonazole, ketoconazole, and miconazole against yeasts of the Candida genus. J. Antimicrob. Chemother. 37(4), 815-819 (1996)
14. Martín-Mazuelos E, Aller AI, Morilla D, Montero O. Antifungal activity of sertaconazole in vitro against clinical isolates of Candida spp. Chemotherapy 42(2), 112-117 (1996).
15. Carrillo-Muñoz AJ, Torres-Rodríguez JM. In vitro antifungal activity of sertaconazole, econazole, and bifonazole against Candida spp. J. Antimicrob. Chemother. 36(4), 713-716 (1995).
16. Carrillo-Muñoz AJ, Brió S, Càrdenes D, Bornay-Llinares F. Sertaconazol. Actividad antifúngica frente a levaduras de interés clínico. Dermatología Peruana. 1, 9-12 (2001).
17. Palacín C, Tarragó C, Ortíz JA. In vitro activity of sertaconazole against Malassezia furfur and pachydermatis in different culture media. Methods Find. Exp. Clin. Pharmacol. 20(6), 451-455 (1998).
18. Carrillo-Munoz AJ, Fernández-Torres B, Guarro, J. In vitro antifungal activity of sertaconazole against 309 dermatophyte clinical isolates. J. Chemother. 15, 555-557 (2003).
19. Carrillo-Munoz AJ, Fernández-Torres B, Cardenes DC, Guarro J. In vitro activity of sertaconazole against dermatophyte isolates with reduced fluconazole susceptibility. Chemotherapy 49(5), 248-251 (2003).
20. Carrillo-Muñoz AJ, Tur C, Estivill D, Torres JM, Estivill D. In vitro antifungal activity of sertaconazole and bifonazole against dermatophytes. J. Mycolog. Med. 5, 235-238 (1995).
21. Torres JM, Carrillo-Muñoz JM, Madrenys-Brunet N. Minimal inhibitory concentrations of sertaconazole, miconazole and clotrimazole on 14 strains of Scopulariopsis brevicaulis isolated from onychomicosis. J. Mycolog. Med. 3, 225-228 (1993).
22. Espinel-Ingroff A. In vitro antifungal susceptibility methods and clinical applications of antifungal resistance. J. Mycol. Med. 38, 293-304 (2000).
23. Odds FC. Should resistance to azole antifungals in vitro be interpreted as predicting clinical non-response? Drug Resist. Update 1, 11-15 (1998).
24. Palacín C, Sacristán A, Ortíz JA. In vitro comparative study of the fungistatic and fungicidal activity of sertaconazole and other antifungals against Candida albicans. Arzneimittelforschung 42(5A), 711-714 (1992).
25. Palacín C, Tarragó C, Agut J, Guglietta A. In vitro activity of sertaconazole, fluconazole, ketoconazole, fenticonazole, clotrimazole and itraconazole against pathogenic vaginal yeast isolates. Methods Find. Exp. Clin. Pharmacol. 23(2), 61-64 (2001).
26. Carrillo-Munoz AJ, Brió S, Quindos G, Palacin C, Guglietta A, Espinel-Ingroff A. Sertaconazole: in vitro antifungal activity against vaginal and other superficial yeast isolates. J. Chemother. 13(5), 555-562 (2001).
27. Palacín C, Sacristán A, Ortíz JA. In vivo activity of sertaconazole in experimental candidiasis in the mouse. Drugs Exp. Clin. Res. 16(9), 469-473 (1990).
28. Palacín C, Sacristán A, Ortíz JA. In vivo activity of sertaconazole in experimental dermatophytosis in guinea-pigs. Arzneimittelforschung 42(5A), 714-718 (1992).
29. Agut J, Tarrida N, Sacristán A, Ortíz JA. Anti-inflammatory activity of topically applied sertaconazole nitrate. Methods Find. Exp. Clin. Pharmacol. 18(4), 233-234 (1996).
30. Alomar C, Bassas S, Casas M et al. Multi-centre double-blind trial on the efficacy and safety of sertaconazole 2% cream in comparison with miconazole 2% cream on patients suffering from cutaneous mycoses. Arzneimittelforschung 42, 767-773 (1992).
31. Nasarre J, Umbert P, Herrero E et al. Therapeutic efficacy and safety of the new antimycotic sertaconazole in the treatment of Pityriasis versicolor. Arzneimittelforschung 42(5A), 764-767 (1992).
32. Fonseca E, Del Pozo J, Marquez M et al. Evaluación de la eficacia y seguridad de Sertaconazol en crema en aplicación única diaria en el tratamiento de las dermatomicosis. Piel 12, 183-188 (1997).
33. Pedragosa R, González B, Martín M et al. Therapeutic efficacy and safety of the new antimycotic sertaconazole in the treatment of cutaneous dermatophytosis. Arzneimittelforschung 42(5A), 760-763 (1992).
34. Umbert P, Nasarre J, Bello A et al. Phase II study of the therapeutic efficacy and safety of the new antimycotic sertaconazole in the treatment of superficial mycoses caused by Candida albicans. Arzneimittelforschung 42(5A), 757-760 (1992).
35. Van Esso D, Fajo G, Losada I et al. Sertaconazole in the treatment of pediatric patients with cutaneous dermatophyte infections. Clin. Ther. 17(2), 264-269 (1995).
36. Dellenbach P, Thomas JL, Guerin V, Ochsenbein E, Contet-Audonneau N. Topical treatment of vaginal candidosis with sertaconazole and econazole sustained-release suppositories. Int. J. Gynaecol. Obstet. 71(Suppl. 1), S47-S52 (2000).
37. Quereux C, Gelas B, Chevallier T, Petit F, Micheletti MC. Evaluation of the efficacy and speed of action of sertaconazole nitrate suppository and cream combined treatment for vulvovaginal candidiasis. Gynecol. Obstet. Fertil. 28(3), 238-244 (2000).
38. Grau MT, Romero A, Sacristán A, Ortíz JA. Acute toxicity studies of sertaconazole. Arzneimittelforschung 42(5A), 725-726 (1992).
39. Romero A, Vilamayor F, Grau MT, Sacristán A, Ortíz JA. Subacute toxicity and maximum tolerable dose of sertaconazole in repeated administration studies. Arzneimittelforschung 42(5A), 727-732 (1992).
40. Romero A, Villamayor F, Grau MT, Sacristán A, Ortíz JA. Chronic toxicity studies of sertaconazole after oral administration to rats and ferrets. Arzneimittelforschung 42(5A), 732-738 (1992).
41. Romero A, Grau MT, Villamayor F, Sacristán A, Ortíz JA. Reproduction toxicity of sertaconazole. Segment II (teratology) and Segment III (peri-postnatal toxicity). Arzneimittelforschung 42(5A), 739-742 (1992)
42. Romero A, Palacín C, Mosesso P et al. Genotoxicity studies on sertaconazole. Arzneimittelforschung 42(5A), 743-745 (1992).
43. Grau MT, Romero A, Sacristán A, Ortíz JA. Dermal tolerance and phototoxicity studies of sertaconazole. Arzneimittelforschung 42(5A), 746-747 (1992).
44. Farré M, Ugena B, Badenas JM, Márquez M, Roset P, Ortíz JA. Pharmacokinetics and tolerance of sertaconazole in man after repeated percutaneous administration. Arzneimittelforschung 42(5A), 752-754 (1992).
45. Romero A, Grau MT, Villamayor F et al. Ocular tolerance of sertaconazole gel. Mycoses 39(1-2), 57-60 (1996).
46. Romaguera C, Herrero E, Márquez M, Torres J, Ortíz JA. Study on the sensitizing capacity of the new antimycotic sertaconazole in the treatment of cutaneous mycoses. Arzneimittelforschung 42(5A), 754-756 (1992).
47. Goday JJ, Yanguas I, Aguirre A, Ilardia R, Soloeta R. Allergic contact dermatitis from sertaconazole with cross-sensitivity to miconazole and econazole. Contact Dermatitis 32(6), 370-371 (1995).
48. Agut J, Moren M, Rego M, Sacristán A, Ortíz JA. Pharmacokinetic evaluation of labelled sertaconazole after dermal application. Arzneimittelforschung 42(5A), 748-751 (1992).
49. Palacin C. Antifungal activity of sertaconazole in the cutaneous retention time test. J. Mycol. Med. 5, 35-39 (1995).
50. Azcona et al. Tolerance and kinetic behaviour after single and repeated vaginal administration of sertaconazole cream and tablets in healthy volunteers. Curr. Ther. Res. 49(6), 1046-1060 (1991).
51. Palacín C, Tarragó C, Ortíz JA. Sertaconazole: pharmacology of a gynecological antifungal agent. Int. J. Gynaecol. Obstet. 71(Suppl. 1), S37-S46 (2000).
52. Perdomo-López I, Rodríguez-Pérez AI, Yzquierdo-Peiro JM et al. Effect of cyclodextrins on the solubility and antimycotic activity of sertaconazole: experimental and computational studies. J. Pharm. Sci. 91(11), 2408-2415 (2002).